Top of this page
Skip navigation, go straight to the content
UCB aspires to be the patient-centric global biopharmaceutical leader transforming the lives of people living with serious diseases.
The company employs over 9 000 people dedicated to the research, development and commercialisation of innovative medicines and patient solutions.
Operating in more than 40 countries, UCB generated revenues of € 3.1 billion in 2009.